Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended-Release Tacrolimus (LCPT) Using Grapefruit Juice
- PMID: 41549771
- PMCID: PMC12813645
- DOI: 10.1002/cpdd.70016
Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended-Release Tacrolimus (LCPT) Using Grapefruit Juice
Abstract
Grapefruit juice (GFJ) is a known inhibitor of intestinal cytochrome P450 3A (CYP3A) metabolism leading to increased exposure to CYP3A substrates such as tacrolimus. The extended-release tacrolimus formulation Envarsus (LCPT) exhibits prolonged absorption throughout the entire GI tract. Although a clinically significant drug-drug interaction occurs with immediate-release tacrolimus formulations, this has not been evaluated with extended-release formulations. This study assessed the impact of GFJ on LCPT in adult kidney transplant patients. Eleven adult kidney transplant recipients on a stable dose of LCPT were enrolled in a randomized crossover study. Participants were administered either GFJ or water during each pharmacokinetic visit, with midazolam used as a positive control. A washout period of 2-4 weeks was included between visits. Tacrolimus concentrations were determined using validated LC-MS/MS methods. Tacrolimus AUC0-24 was 28% higher with GFJ (GMR = 1.28, 90% CI 1.12-1.44) and Cmax was 73% higher (GMR = 1.73, 90% CI 1.46-2.00) compared to control. GFJ exhibited a clinically meaningful interaction with LCPT. However, the magnitude appears less than those reported with immediate-release formulations, suggesting the extended absorption profile of LCPT may affect susceptibility to drug interactions in the intestine.
Keywords: Envarsus; LC‐MS/MS; cytochrome P450 3A; drug–drug interactions; grapefruit juice; midazolam; tacrolimus.
© 2026 The Author(s). Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Conflict of interest statement
Shirley M. Tsunoda received funding from Veloxis Pharmaceuticals; all other co‐authors declare no conflicts of interest.
Figures
References
-
- Taylor PJ, Hogan NS, Lynch SV, Johnson AG, Pond SM. Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry. Clin Chem. 1997;43(11):2189‐2190. - PubMed
-
- Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391‐396. - PubMed
-
- Gertz M, Davis J, Harrison A, Houston J, Galetin A. Grapefruit juice‐drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab. 2008;9(8):785‐795. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
